Xiaohua H. Hou

Union Hospital
Wuhan, 430022, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 81 publications

Corrigendum to "International clinical practice guideline on the use of traditional Chinese medicine for functional dyspepsia (2025)". [J. Integrat. Med. 23 (2025) 502-518].

Corrigendum to "International clinical practice guideline on the use of traditional Chinese medicine for functional dyspepsia (2025)". [J. Integrat. Med. 23 (2025) 502-518].

Journal: Journal of integrative medicine

Published: February 07, 2026

Phocaeicola vulgatus improves anxiety-like behavior by ameliorating amygdala neuroinflammation and the neurite impairment in IBS.

Phocaeicola vulgatus improves anxiety-like behavior by ameliorating amygdala neuroinflammation and the neurite impairment in IBS.

Journal: Translational psychiatry

Published: December 03, 2025

Candidalysin drives pyroptosis of intestinal epithelium to exacerbate IBS by suppressing HDAC2-mediated deacetylation of GSDMD-K194.

Candidalysin drives pyroptosis of intestinal epithelium to exacerbate IBS by suppressing HDAC2-mediated deacetylation of GSDMD-K194.

Journal: Journal of advanced research

Published: November 16, 2025

Multitarget actions of TongXie-Ning granules against the gut dysfunctions of diarrhea-predominant irritable bowel syndrome.

Multitarget actions of TongXie-Ning granules against the gut dysfunctions of diarrhea-predominant irritable bowel syndrome.

Journal: Journal of ethnopharmacology

Published: August 23, 2025

CAR-Cell Therapy for Autoimmune Diseases: From the Laboratory to Clinical Practice.

CAR-Cell Therapy for Autoimmune Diseases: From the Laboratory to Clinical Practice.

Journal: Journal of immunology research

Published: July 24, 2025

Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Journal: Drugs

Published: June 04, 2025

Impact of four-week rifaximin treatment on abdominal symptoms, psychological state and gut microbiome in diarrhea-predominant irritable bowel syndrome: a pilot study.

Impact of four-week rifaximin treatment on abdominal symptoms, psychological state and gut microbiome in diarrhea-predominant irritable bowel syndrome: a pilot study.

Journal: European journal of pharmacology

Published: May 12, 2025

Second Asian Consensus Report on Functional Dyspepsia (2025): Updated Recommendations.

Second Asian Consensus Report on Functional Dyspepsia (2025): Updated Recommendations.

Journal: Journal of gastroenterology and hepatology

Published: May 08, 2025

Endoscopic findings in patients with chronic bloating/abdominal distension and the effect of the transition from the Rome III to Rome IV criteria: a multicenter cross-sectional study.

Endoscopic findings in patients with chronic bloating/abdominal distension and the effect of the transition from the Rome III to Rome IV criteria: a multicenter cross-sectional study.

Journal: BMC gastroenterology

Published: April 19, 2025

Addition of bedtime lafutidine inhibits nocturnal acid-breakthrough and improves sleep quality in gastroesophageal reflux disease patients on esomeprazole: a randomized controlled trial.

Addition of bedtime lafutidine inhibits nocturnal acid-breakthrough and improves sleep quality in gastroesophageal reflux disease patients on esomeprazole: a randomized controlled trial.

Journal: Scientific reports

Published: February 19, 2025

Comprehensive Benefit Evaluation and Clinical Decision-Making After 4-week Cinitapride Treatment on Functional Dyspepsia: A Multicenter, Prospective Designed, Real-World Study.

Comprehensive Benefit Evaluation and Clinical Decision-Making After 4-week Cinitapride Treatment on Functional Dyspepsia: A Multicenter, Prospective Designed, Real-World Study.

Journal: Digestive diseases and sciences

Published: December 12, 2024

Role of declined electrogenic Na+/HCO3- cotransporter NBCe1 in mucus barrier impairment and colonic inflammation.

Role of declined electrogenic Na+/HCO3- cotransporter NBCe1 in mucus barrier impairment and colonic inflammation.

Journal: International immunopharmacology

Published: December 04, 2024

Showing 1-12 of 81

Last Updated: 09/26/2026